CivicaScript LLC, a nonprofit focused on bringing low-cost generic medicines to US patients, announced on Thursday that it has launched its droxidopa in the United States.
Droxidopa is intended for the treatment in adults of certain types of orthostatic dizziness, light-headedness or the 'feeling that you are about to black out'.
The company will be providing droxidopa 300mg capsules for sale to pharmacies from 10 April, priced at USD132 per bottle of 90 capsules. It has been recommended that pharmacies charge patients no more than USD153 per bottle.
CivicaScript will offer 100 mg, 200 mg and 300 mg strengths of droxidopa capsules.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream